Publicaciones en colaboración con investigadores/as de University of Milan (72)

2024

  1. 3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

    The Lancet, Vol. 403, Núm. 10437, pp. 1649-1659

  2. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)

    Breast, Vol. 76

  3. A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases

    Annals of Oncology

  4. Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab

    Breast Cancer Research and Treatment, Vol. 205, Núm. 3, pp. 589-598

  5. Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: should health authorities consider post hoc data to inform priority access?

    ESMO Open, Vol. 9, Núm. 9

  6. Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO)

    Radiotherapy and Oncology, Vol. 195

  7. Immunotherapy in the treatment landscape of hormone receptor-positive (HR+) early breast cancer: is new data clinical practice changing?

    ESMO Open

  8. International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations

    The Lancet Oncology, Vol. 25, Núm. 2, pp. e73-e83

  9. Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer

    Cancer Treatment Reviews, Vol. 128

  10. Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)

    ESMO Open, Vol. 9, Núm. 3

  11. Sacituzumab govitecan for hormone receptor–positive HER2-negative advanced breast cancer

    Expert Review of Anticancer Therapy, Vol. 24, Núm. 10, pp. 949-958

  12. Surrogate endpoints for overall survival in randomized clinical trials testing immune checkpoint inhibitors: a systematic review and meta-analysis

    Frontiers in Immunology, Vol. 15

  13. The evolving value assessment of cancer therapies: Results from a modified Delphi study

    Health Policy OPEN, Vol. 6

  14. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial

    ESMO Open, Vol. 9, Núm. 5

  15. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

    Nature Medicine, Vol. 30, Núm. 8, pp. 2208-2215

  16. Window of opportunity trials with immune checkpoint inhibitors in triple-negative breast cancer

    ESMO Open, Vol. 9, Núm. 10

2023

  1. Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical Trial

    JAMA Network Open, Vol. 6, Núm. 4, pp. E235822

  2. Correction to: Improving clinical paediatric research and learning from COVID-19: recommendations by the Conect4Children expert advice group (Pediatric Research, (2022), 91, 5, (1069-1077), 10.1038/s41390-021-01587-3)

    Pediatric Research

  3. DESTINY-Breast03 trial: some questions remain – Authors' reply

    The Lancet

  4. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

    Annals of Oncology, Vol. 34, Núm. 8, pp. 645-659